Cargando…

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. PET/CT using PSMA is more sensitive than choline PET/CT. (177)Lu-PSMA radioligand therapy is mainly used for patients with end-stage prostate cancer. This report...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Eyben, Finn E., Kiljunen, Timo, Joensuu, Timo, Kairemo, Kalevi, Uprimny, Christian, Virgolini, Irene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630396/ https://www.ncbi.nlm.nih.gov/pubmed/29029496 http://dx.doi.org/10.18632/oncotarget.19805

Ejemplares similares

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

(177)Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: von Eyben, Finn E., et al.
Publicado: (2021)

Single Center Experience with a 4-Week (177)Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Kemppainen, Jukka, et al.
Publicado: (2022)

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
por: Groener, Daniel, et al.
Publicado: (2021)

Renal Safety of [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
por: Rosar, Florian, et al.
Publicado: (2021)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2020)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
por: Zisser, Lucia, et al.
Publicado: (2022)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Efficacy and Safety of [(225)Ac]Ac-PSMA-617 Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
por: Rosar, Florian, et al.
Publicado: (2021)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
por: Seifert, Robert, et al.
Publicado: (2020)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Bone marrow impairment during early [(177)Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
por: Kind, Felix, et al.
Publicado: (2022)

RadioLigand Therapy with [(177)Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
por: Terroir, Marie, et al.
Publicado: (2023)

Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2016)

Outcome of (177)Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2021)

A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
por: Wang, Guochang, et al.
Publicado: (2022)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Kessel, Katharina, et al.
Publicado: (2020)

Salvage Radioligand Therapy with Repeated Cycles of (177)Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
por: Groener, Daniel, et al.
Publicado: (2021)

Long-term outcome of (177)Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2021)

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy
por: Gaal, Sebastian, et al.
Publicado: (2023)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
por: Seifert, Robert, et al.
Publicado: (2020)

Early PSA Change after [(177)Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival
por: Kind, Felix, et al.
Publicado: (2021)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
por: Kairemo, Kalevi, et al.
Publicado: (2015)

Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy
por: Rosar, Florian, et al.
Publicado: (2021)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_40qvvl0680ud8ov06cvng28jhd